Haqq Christopher 4
4 · Elicio Therapeutics, Inc. · Filed Jul 17, 2026
Research Summary
AI-generated summary of this filing
Elicio (ELTX) EVP Christopher Haqq Receives 64,643-Share Option Award
What Happened
Christopher Haqq, Executive Vice President, Head of R&D and Chief Medical Officer of Elicio Therapeutics (ELTX), received an equity award on July 16, 2026 covering 64,643 shares. The reported acquisition price is $0.00 because this was an option/award (derivative), not a market purchase or sale. No shares were sold or exercised in this transaction.
Key Details
- Transaction date: 2026-07-16 (Form 4 filed 2026-07-17).
- Transaction type/code: Award/Grant (derivative) — reported as "A".
- Amount: 64,643 shares (stock option grant) at $0.00 reported price.
- Vesting: 50% vests on July 16, 2027 and the remaining 50% vests on July 16, 2028, subject to continued service (per filing footnote).
- Shares owned after transaction: not specified in the information provided in this summary.
- Timeliness: filing appears timely (reported period 7/16/2026, filed 7/17/2026).
Context
This was a grant of options/awards that vest over two years — a common executive compensation/retention tool. Because it’s a derivative grant (not an open-market purchase or sale), it does not represent an immediate cash outlay or a direct buy/sell signal; future vesting and any exercise would be separate events disclosed later.
Insider Transaction Report
- Award
Stock Option (Right to Buy)
[F1]2026-07-16+64,643→ 64,643 totalExercise: $3.20Exp: 2036-07-16→ Common Stock (64,643 underlying)
Footnotes (1)
- [F1]The stock option vests and becomes exercisable as to 50% of the options on July 16, 2027, the first anniversary of the grant date, and as to the remaining 50% of the options on July 16, 2028, the second anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.